Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term
- Department of Pediatrics, University of Alberta, Edmonton, Canada
- Correspondence to
: Joanna E MacLean
Department of Pediatrics, University of Alberta, 4–590 Edmonton Clinic Health Academy, 11415 87th Avenue NW, Edmonton, Alberta, Canada T6G 1C9;
Commentary on: Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics 2012;130:e575–80.
Obstructive sleep apnoea (OSA) is a common condition affecting 1–5% of children. The most common cause of OSA in childhood is adenotonsillar hypertrophy which is mediated by inflammation. While anti-inflammatory therapy is commonly trialled as a treatment strategy in mild forms, there is a paucity of literature to support this treatment strategy for children with OSA.
This study by Goldbart and colleagues was conducted in a single tertiary care centre in a metropolitan area. This is a double-blind randomised placebo-controlled trial of montelukast for the treatment of non-severe OSA in children. The population for recruitment was children referred for evaluation of snoring. Subjects were 2–10 years of age, had habitual snoring, non-severe OSA (defined as an apnoea/hypopnoea index <10 events/h) and were naïve to montelukast therapy as well as adenotonsillectomy. Children were excluded if they …